{"prompt": "['CONFIDENTIAL', 'Protocol ANB019-002 - Amendment 5', \"8.1.4 Generalized Pustular Psoriasis Physician's Global Assessment Scale\", 'Description of the change: New section added to describe the GPPPGA scale.', 'Purpose of the change: This assessment scale was added as a secondary endpoint to assess', 'the impact of GPP at each study visit. Appendix 12 was also added to include the scale.', '8.2.4 Electrocardiograms', 'Description of the change: Clarified that ECGs will be reviewed by the central laboratory', '\"for quality and interpretation\" and that ECG data would not be entered into EDC with the', 'exception of clinical significance.', \"Purpose of the change: To reduce confusion over procedures and clarify the central lab's role\", 'in ECG processing.', '8.2.6 Photography', 'Description of the change: Language was revised to describe a standardized approach for', 'collection of photographs and the process for transfer and quality review.', 'Purpose of the change: To provide further guidance and clarity.', '8.2.8 Telephone Contact', 'Description of the change: Added this section to clarify the visits that are phone contact only', 'versus site visits.', 'Purpose of the change: To clarify visit purpose and procedures for phone contact.', '8.5 Pharmacokinetics', 'Description of the change: Added Table 2 to outline the collection schedule for', 'pharmacokinetic assessments during the study.', 'Purpose of the change: To clarify PK collection time points.', '8.7 Genetics', 'Description of the change: Revised language to characterize additional DNA/RNA testing', 'and optional pharmacogenomic testing', 'Purpose of the change: To align with revisions made to exploratory endpoints for PK and', 'pharmacogenomics', '9.3 Populations for Analyses', 'Description of the change: Updated Table 3 to describe analysis populations.', 'Purpose of the change: To better align with the statistical analysis plan for this study.', '9.4.4 Efficacy Analyses', 'Description of the change: Added additional text to support the added efficacy endpoint for', 'the GPPPGA at Weeks 1 through 16.', 'Purpose of the change: To describe the analysis associated with this endpoint.', '29 October 2019', '91']['CONFIDENTIAL', 'Protocol ANB019-002 - Amendment 5', '9.4.6 Immunogenicity Analyses', 'Description of the change: added description of how statistical data will be presented', 'Purpose of the change: Text added to better characterize the presentation of statistical data for', 'ADA status and efficacy and safety endpoints', '9.4.8 Biomarker Analyses', 'Description of the change: Removed the following sentences - Results will be presented in', 'terms of 95% CIs. In addition, the n, mean, SD, median, minimum and maximum will also be', 'prevented.', 'Purpose of the change: To clarify language in this section, as well as presentation of data.', '10', 'References', 'Description of the change:', 'Added the following reference: A Double-Blind, Randomized, Placebo-Controlled,', 'Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Study to', 'Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of', 'ANB019 in Healthy Subjects and Psoriasis Patients. Protocol No.: ANB019-001.', 'Clinical Study Report. 22 June 2018', 'Added the following reference: Bachelez H, Choon SE, Marrakchi S, et al.', 'Inhibition of the IL-36 Pathway for the Treatment of Generalized Pustular', 'Psoriasis. N Engl J Med 2019; 380:(10).', 'Added the following reference: Marrakchi S, Burden A, Tsai T, et al. Inhibition of', 'the Interleukin-36 Pathway for the Treatment of Generalized Pustular Psoriasis', '[To the Editor]. N. Engl. J. Med. 2019; 380:10.', 'Purpose of the change:', 'To provide a citation for clinical trial data and information provided in Section 2.', 'To provide a citation for the GPPPGA scale in the objectives and endpoints, as well', 'as Appendix 11.', 'To provide a citation for the description of the GPPPGA scale in Section 8.1.4.', 'Appendix 8 Signature of Investigator', 'Description of the change: Removed this appendix and renumbered remaining appendices.', \"Purpose of the change: Moved the Investigator's signature up to immediately follow the\", \"Sponsor's signature at the beginning of the document to better align with AnaptysBio\", 'preferences for protocol organization.', \"Appendix 11 Generalized Pustular Psoriasis Physician's Global Assessment\", 'Description of the change: New appendix was added.', '29 October 2019', '92']\n\n###\n\n", "completion": "END"}